- CStone to receive $150M up front and $1.15B as milestones for both drugs along with royalties on each drug. EQRx get an exclusive right to lead global development and commercialization excluding Mainland China, Taiwan, Hong Kong, and Macau
- CStone retains rights to CS1003 in Greater China, where it will pursue development as a monothx. or as part of its combination strategy for the therapy
- Sugemalimab is an investigational anti-PD-L1 mAb and showed antitumor activity in multiple tumor types and was well-tolerated in P-I dose-escalation study in China. CS1003 is a humanized recombinant IgG4 mAb targeting PD-1, being developed for immunotherapy of various tumors
Click here to read full press release/ article | Ref: PRNewswire | Image: Under 30 CEO
The post CStone Signs an Out-Licensing Agreement with EQRx for Sugemalimab and CS1003 first appeared on PharmaShots.